| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.30▲ | 1.32▼ | 1.34▼ | 1.37▼ | 1.35▼ |
| MA10 | 1.31▼ | 1.34▼ | 1.36▼ | 1.39▼ | 1.39▼ |
| MA20 | 1.34▼ | 1.36▼ | 1.37▼ | 1.36▼ | 1.16▲ |
| MA50 | 1.34▼ | 1.38▼ | 1.43▼ | 1.37▼ | 1.48▼ |
| MA100 | 1.37▼ | 1.41▼ | 1.34▼ | 1.11▲ | 1.52▼ |
| MA200 | 1.40▼ | 1.34▼ | 1.36▼ | 1.31▼ | 2.12▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.005▼ | -0.007▼ | -0.004▼ | 0.041▲ |
| RSI | 39.934▼ | 37.978▼ | 39.128▼ | 47.837▼ | 50.476▲ |
| STOCH | 16.667▼ | 26.588 | 15.342▼ | 39.568 | 51.598 |
| WILL %R | -89.474▼ | -90.909▼ | -94.595▼ | -71.053 | -47.712 |
| CCI | -42.084 | -139.956▼ | -123.687▼ | -33.757 | 26.766 |
| RSI | $IFRX RSI(14) Crossed Below 50 | Set Alert |
| ▼ MACD | $IFRX MACD(12,26,9) Crossed Below Signal Line | Set Alert |
| MA | $IFRX Price Crossed Below MA(200) | Set Alert |
| MA | $IFRX Price Crossed Below MA(50) | Set Alert |
| MA | $IFRX Price Crossed Below MA(26) | Set Alert |
| MA | $IFRX Price Crossed Below MA(13) | Set Alert |
| ▼ GAP | $IFRX Open Gap Down %2 | Set Alert |
|
Friday, October 24, 2025 09:47 AM
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.
|
|
Tuesday, October 21, 2025 04:34 AM
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities ...
|
|
Tuesday, October 21, 2025 12:20 AM
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/11/25 | 1.34 | 1.345 | 1.295 | 1.305 | 204,824 |
| 03/11/25 | 1.44 | 1.48 | 1.32 | 1.38 | 554,198 |
| 31/10/25 | 1.32 | 1.46 | 1.32 | 1.46 | 320,165 |
| 30/10/25 | 1.43 | 1.47 | 1.30 | 1.32 | 769,141 |
| 29/10/25 | 1.55 | 1.55 | 1.35 | 1.38 | 768,138 |
| 28/10/25 | 1.65 | 1.65 | 1.4801 | 1.51 | 928,949 |
| 27/10/25 | 1.42 | 1.71 | 1.355 | 1.66 | 1,958,243 |
| 24/10/25 | 1.24 | 1.42 | 1.22 | 1.40 | 1,084,533 |
| 23/10/25 | 1.27 | 1.34 | 1.20 | 1.22 | 381,099 |
| 22/10/25 | 1.38 | 1.38 | 1.24 | 1.27 | 743,435 |
|
|
||||
|
|
||||
|
|